Get started

Okayama City General Medical Center

Alternate names: 地方独立行政法人岡山市立総合医療センター, 岡山市立総合医療センター
ROR: 01dj4ez18
OpenAlex ID: I4405254092
Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
2021 · Masatoshi Kudo, Yusuke Kawamura, et al. · Liver Cancer · 711
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
2018 · Atsushi Hiraoka, Takashi Kumada, et al. · Liver Cancer · 268
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
2017 · Atsushi Hiraoka, Takashi Kumada, et al. · Liver Cancer · 221
JCS/JHRS 2019 Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias
2021 · Akihiko Nogami, Takashi Kurita, et al. · Circulation Journal · 214
PDF
JCS/JHRS 2019 guideline on non‐pharmacotherapy of cardiac arrhythmias
2021 · Akihiko Nogami, Takashi Kurita, et al. · Journal of Arrhythmia · 169
Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
2019 · Atsushi Hiraoka, Takashi Kumada, et al. · Cancer Medicine · 161
PDF
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
2022 · Andrea Casadei-Gardini, Margherita Rimini, et al. · European Journal of Cancer · 143
PDF
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis
2022 · M. Rimini, L. Rimassa, et al. · ESMO Open · 132
PDF
Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis
2018 · Atsushi Hiraoka, Takashi Kumada, et al. · Cancer Medicine · 131
PDF
Complications of radiofrequency ablation for hepatocellular carcinoma in a multicenter study: An analysis of 16 346 treated nodules in 13 283 patients
2012 · Masahiko Koda, Yoshikazu Murawaki, et al. · Hepatology Research · 116
Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies
2022 · Rosyli F. Reveron‐Thornton, Margaret L. P. Teng, et al. · Hepatology Communications · 104
PDF
WRN Mutation Update: Mutation Spectrum, Patient Registries, and Translational Prospects
2016 · Koutaro Yokote, Sirisak Chanprasert, et al. · Human Mutation · 104
PDF
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
2018 · Atsushi Hiraoka, Takashi Kumada, et al. · Hepatology Research · 95
PDF
Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial
2024 · Kiyohiro Houkin, Toshiya Osanai, et al. · JAMA Neurology · 91
PDF
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study
2022 · Takeshi Hatanaka, Satoru Kakizaki, et al. · Hepatology International · 88
PDF
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
2020 · Toshifumi Tada, Takashi Kumada, et al. · Liver International · 87
PDF
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice
2022 · Takaaki Tanaka, Atsushi Hiraoka, et al. · Hepatology Research · 84
PDF
Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma
2019 · Atsushi Hiraoka, Takashi Kumada, et al. · Oncology · 82
Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients
2019 · Masaki Maeda, Issei Saeki, et al. · Liver Cancer · 77
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
2021 · Atsushi Hiraoka, Takashi Kumada, et al. · Cancer Reports · 76
EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis
2020 · Kazuya Kariyama, Kazuhiro Nouso, et al. · Liver Cancer · 74
Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
2020 · Kentaro Ejiri, Toru Miyoshi, et al. · Journal of the American Heart Association · 73
PDF
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients
2023 · Mara Persano, Margherita Rimini, et al. · European Journal of Cancer · 68
PDF
Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis
2022 · Toshifumi Tada, Takashi Kumada, et al. · European Journal of Gastroenterology & Hepatology · 65
Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer
2018 · Hideaki Kinugasa, Kazuhiro Nouso, et al. · Cancer Biology & Therapy · 63
PDF
Works count: 71
Works count with child institutions: 780
Citation count: 610
Year
Topic
Type